Intraluminal drug and formulation behavior and integration in in vitro permeability estimation:: A case study with amprenavir

被引:81
作者
Brouwers, J
Tack, J
Lammert, F
Augustijns, P
机构
[1] Katholieke Univ Leuven, Lab Pharmacotechnol & Biopharm, B-3000 Louvain, Belgium
[2] Univ Hosp Leuven, Dept Gastroenterol, B-3000 Louvain, Belgium
[3] Univ Hosp Bonn, Dept Internal Med 1, D-53105 Bonn, Germany
关键词
Caco-2; cells; intestinal absorption; amprenavir; TPGS; P-glycoprotein; biorelevance; human intestinal fluid;
D O I
10.1002/jps.20553
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The purpose of this study was to assess the effect of biorelevant apical conditions on intestinal permeability estimation in the Caco-2 system for amprenavir, a poorly water-soluble substrate of the efflux carrier P-glycoprotein (P-gp). To establish biorelevant conditions, human intestinal fluids (HIF) were aspirated from the duodenum and jejunum in fasted subjects, before and during 4 h after the intake of a standard formulation of amprenavir (Agenerase(R)). The HIF samples were characterized with respect to the concentrations of phospholipids, individual bile salts, amprenavir, and the excipient d-alpha-tocopheryl polyethyleneglycol 1000 succinate (TPGS); subsequently, the use of these samples in the Caco-2 system during permeability estimation for amprenavir was compared to standard conditions (amprenavir 10 mu M dissolved in HBSS-based transport medium). The presence of the solubilizing excipient TPGS resulted in high intraluminal amprenavir concentrations (mM-range) and affected the permeability in a concentration-dependent way. At the observed intraluminal TPGS concentrations (mM-range), TPGS appeared to completely inhibit the interaction between amprenavir and P-gp, suggesting that the effect of P-gp on transepithelial transport of amprenavir in a clinical setting is probably negligible. This study illustrates the importance of the evaluation of intraluminal conditions after drug intake and their integration in permeability estimation in vitro. (C) 2005 Wiley-Liss, Inc. and the American Pharmacists Association.
引用
收藏
页码:372 / 383
页数:12
相关论文
共 29 条
  • [1] Transport activity of human MRP3 expressed in Sf9 cells: Comparative studies with rat MRP3
    Akita, H
    Suzuki, H
    Hirohashi, T
    Takikawa, H
    Sugiyama, Y
    [J]. PHARMACEUTICAL RESEARCH, 2002, 19 (01) : 34 - 41
  • [2] P-glycoprotein and surfactants: Effect on intestinal talinolol absorption
    Bogman, K
    Zysset, Y
    Degen, L
    Hopfgartner, G
    Gutmann, H
    Alsenz, J
    Drewe, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (01) : 24 - 32
  • [3] BOUDREAUX JP, 1993, TRANSPLANT P, V25, P1875
  • [4] Determination of intraluminal theophylline concentrations after oral intake of an immediate- and a slow-release dosage form
    Brouwers, J
    Ingels, F
    Tack, J
    Augustijns, P
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2005, 57 (08) : 987 - 995
  • [5] The effect of water-soluble vitamin E On cyclosporine pharmacokinetics in healthy volunteers
    Chang, T
    Benet, LZ
    Hebert, MF
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (03) : 297 - 303
  • [6] P-glycoprotein attenuating effect of human intestinal fluid
    Deferme, S
    Tack, J
    Lammert, F
    Augustijns, P
    [J]. PHARMACEUTICAL RESEARCH, 2003, 20 (06) : 900 - 903
  • [7] Plasma alpha-tocopherol concentrations after supplementation with water- and fat-soluble vitamin E
    Dimitrov, NV
    MeyerLeece, C
    McMillan, J
    Gilliland, D
    Perloff, M
    Malone, W
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1996, 64 (03) : 329 - 335
  • [8] Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS)
    Dintaman, JM
    Silverman, JA
    [J]. PHARMACEUTICAL RESEARCH, 1999, 16 (10) : 1550 - 1556
  • [9] Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms
    Dressman, JB
    Amidon, GL
    Reppas, C
    Shah, VP
    [J]. PHARMACEUTICAL RESEARCH, 1998, 15 (01) : 11 - 22
  • [10] Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs
    Galia, E
    Nicolaides, E
    Hörter, D
    Löbenberg, R
    Reppas, C
    Dressman, JB
    [J]. PHARMACEUTICAL RESEARCH, 1998, 15 (05) : 698 - 705